100% Pharma Tariffs, Lilly's Oral GLP-1 Approval, and a $12B Week in Biotech M&A – This Week in Biotech #94
Orforglipron becomes the first oral weight loss pill approved without food or water timing restrictions, Biogen buys Apellis, and trade policy just became every board's new headache (3/27-4/2, 2026).
Welcome back to This Week in Biotech by Biotech Blueprint, edition 94, covering biotech and biopharma news from March 27th to April 2nd, 2026.
🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.
🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.
👥 If you haven’t already, please connect with me or follow me on LinkedIn.
VIDEO SUMMARY
THIS WEEK’S KEY TAKEAWAYS 🔑
Eli Lilly paired a fast regulatory win for Foundayo (orforglipron) with a large strategic acquisition of Centessa, while Biogen bought Apellis for near term commercial cash flow and nephrology field infrastructure. Those moves all point to thee fact that large buyers are still willing to pay real money, but mostly when uncertainty is constrained and launch math is visible.
Yesterday, the White House moved to impose 100% tariffs on a subset of branded pharmaceutical imports from countries without qualifying trade arrangements, with carveouts and phased implementation language shaping the near term impact. The immediate business effect is not simple demand destruction. It is supply chain repricing risk, gross margin uncertainty, and fresh pressure to localize active pharmaceutical ingredient and finished dose manufacturing for politically exposed products. Even before full implementation details settle, boards now have to model trade policy as a core variable.
The obesity narrative also got more strategic in the last 48 hours. Lilly now has the first approved oral small molecule GLP-1 option for chronic weight management that can be taken without food or water timing constraints. Novo Nordisk quickly challenged comparative claims in public, which is exactly what a mature two player market looks like when convenience and efficacy are both investable endpoints. This no longer reads like a single winner category. It reads like a multiyear channel battle across adherence, payer access, and real world persistence.
Clinical data reinforced a stricter quality bar. Immunovant reported that batoclimab failed both pivotal thyroid eye disease studies on the primary endpoint, while Beam continued to publish early but encouraging base editing data in sickle cell disease. The market is being pretty blunt. Late stage misses get punished immediately, and early platform wins only matter if they keep turning into durable efficacy with strong execution.
BIOTECH/PHARMA NEWS 🧬
🔹 U.S. administration signed an order setting 100% tariffs on certain imported branded drugs and active pharmaceutical ingredients from countries without qualifying trade deals, with carveouts that appear designed to limit immediate disruption while preserving political leverage. For operating teams, the implication is not just customs cost pass through. It is contract manufacturing renegotiation, product specific sourcing triage, and potential gross to net pressure if pricing actions face payer resistance. Investors now need to underwrite policy implementation risk product by product, not simply at sector level.
🔹 Eli Lilly consolidated an unusually strong week by combining regulatory speed and strategic M&A. The FDA approved Foundayo (orforglipron) for chronic weight management in adults with obesity, or overweight with at least one weight related comorbidity, and did so 50 days after filing under the Commissioner’s National Priority Voucher program. Lilly then announced the acquisition of Centessa for $38/share in cash, valuing the transaction at about $6.3B upfront, plus a contingent value right worth up to $9 per share linked to orexin receptor 2 program milestones. The strategic logic is that obesity generated scale is being recycled into adjacent, high value chronic disease franchises where first movers can still build durable share.
🔹 Merck signed a collaboration that could reach $838M in milestones for antibody candidates generated against multiple undisclosed targets, with economics weighted to downstream achievements. The headline matters less than the structure. Large pharma still wants external biologics throughput, but prefers options and staged risk transfer over heavy upfront checks for preclinical stories. That framework raises the execution burden for platform companies: it is no longer enough to show technical novelty, you need repeatable asset quality and partner relevant timelines.
🔹 Biogen agreed to acquire Apellis for $41 per share in cash, approximately $5.6B upfront, with additional contingent value rights tied to Syfovre sales milestones. The deal adds two marketed complement pathway products and an established nephrology commercial footprint while Biogen advances internal kidney programs. Apellis reported $690M in 2025 net product revenues across Syfovre and Empaveli, which gives Biogen immediate top line contribution rather than a long precommercial wait. In this funding tape, that is exactly the type of asset profile that clears internal return hurdles for large buyers.
🔹 IO Biotech moved toward bankruptcy after failing to secure a buyer or financing path following pivotal disappointment in its cancer vaccine program. The company disclosed intent to seek bankruptcy protection, underscoring how quickly a late stage miss plus weak capital access can collapse strategic optionality. This is the opposite side of the same market that rewarded large cap buyers this week. Capital exists, but it is selective and often binary around data credibility and near term commercial visibility.
CLINICAL TRIAL UPDATES 📊
🔹 Batoclimab (Immunovant) - Phase 3, thyroid eye disease: Immunovant reported that both pivotal studies, TIDE-1 and TIDE-2, missed the primary endpoint of at least a 2 millimeter reduction in proptosis at Week 24 versus placebo. The company also said one secondary endpoint, diplopia responder rate, was not statistically significant in either study, while another secondary endpoint, Clinical Activity Score of 0 or 1, reached statistical significance in one trial but not the other. Safety was described as generally consistent with prior batoclimab experience, with no newly identified signal that altered overall interpretation. This was not a clean enough efficacy package to support a credible TED path for batoclimab, and management signaled focus would remain on next generation FcRn assets.
🔹 BEAM-101 (risto-cel) (Beam Therapeutics) - Phase 1/2, sickle cell disease: Beam announced publication of BEACON data in The New England Journal of Medicine, reinforcing the early thesis that base editing can durably raise fetal hemoglobin and reduce vaso occlusive events in treated patients. Patient counts remain limited and follow up is still maturing, so this is not yet a registrational level dataset. But the translational signal continues to hold up across company updates and peer reviewed presentation, which keeps the platform competitive in the broader one time treatment race for hemoglobinopathies. The practical next step is scaling enrollment and durability follow up while demonstrating manufacturing consistency at higher throughput.
WATCHLIST 👀
U.S. pharma tariff implementation details: country scope, product exemptions, and active pharmaceutical ingredient treatment will drive near term margin modeling and supply chain changes.
Orca Bio, Orca-T: FDA extended review to July 6 after additional chemistry, manufacturing, and controls submission.
Viridian Therapeutics, REVEAL-2: chronic thyroid eye disease Phase 3 readout expected in Q2, key for commercial positioning after REVEAL-1 debate.
Lilly vs Novo oral obesity positioning: comparative messaging fight will likely shift quickly toward payer contracts and persistence data.
Biogen integration of Apellis assets: early commercial execution and nephrology channel retention will signal whether the deal thesis converts into growth.
Have a great rest of your week and thanks for reading Biotech Blueprint!
DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.
DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.
LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.
Cover image credit: Andrew Leyden/NurPhoto via AP